SwitzerlandSwitzerland

Santhera publishes pivotal trial results of idebenone and goes for EU approval

26.07.2011

Liestal/Newscastle – Swiss Santhera Pharmaceuticals and researchers from Newcastle University have published results from a pivotal clinical trial demonstrating that the firm’s synthetic coenzyme Q10 derivative idebenone significantly improves vision and perception of colour in a subgroup of patients with the rare mitochondrial disease Leber's Hereditary Optic Neuropathy (LHON). The 10,000 to 20,000 patients in Europe and the US, which suffer from the maternally inherited condition, initially lose the sight in one eye due to a malfunction of complex I of the mitochondrial respiratory chain and subsequent retinal apoptosis. Typically, they lose the sight in their other eye within the next 3 to 6 months (so called discordant visual acuity). Researchers from Newcastle, Munich, and Montreal now demonstrated for the first time in 85 patients, that treatment with a 900mg dose of idebenone over two years could significantly improve visual acuity in a patient subgroup carrying the G11778A or G3460A mitochondrial DNA mutations, which are found in 80% of all LHON patients.
The Newscastle group led by Professor Patrick Chinnery reported that idebenone treatment resulted in a marked improvement of vision in severely affected patients, who were not able to read any letter on a chart. In nine blind patients (12 eyes) out of 36 patients (61 eyes) taking idebenone, vision improved to an extent that patients were able to read at least one row of letters on the chart (20%). In contrast not a single patient of the 26 who were taking the placebo improved to that extent.
The results published in yesterday’s issue of BRAIN are part of a data package accepted by the EU drug authority on July 22th which now reviews the firm’s MAA in this indication. Market approval in LHON could be expected at the end of 2012 earliest, according to the Swiss specialist for neuromuscular diseases. The drug will be available trough a Named Patient Programme until the EMA has come to a decision. The greatest improvement was seen in patients who had deteriorated in one eye more than the other. The RHODOS study does not deliver data from patients who have been affected from the disease for more than 5 years. Idebenone has already gotten market approval in Canada as treatment for Friedreichs ataxia but was rejected the the EMA in this indication.

SwitzerlandSwitzerland

11.11.2011

Ghent/Geneva - Ablynx rides the biotech rollercoaster. Only days after US-pharma company Pfizer pulled out of a rheumatoid arthritis pact, the Belgian bipharmaceutical outfit expanded its relationship with Merck Serono. Ablynx...

SwitzerlandSwitzerland

10.11.2011

Alschwil - Actelion Ltd. gets a badly needed injection of fresh capital. Under the guidance of the two biggest Swiss banks, UBS and Credit Suisse, the Swiss biopharmaceutical company takes up €171 million agreeing to pay a 4,875%...

SwitzerlandSwitzerland

18.10.2011

Basel/San Diego –Swiss drug company Roche has announced it is buying biotech-company Anadys Pharmaceuticals for US$230 million. Under the terms of the merger agreement, Roche will commence an all cash tender offer for all...

Germany, SwitzerlandSwitzerland

12.10.2011

The Swiss technology transfer organisation Unitectra is the winner of the European Biotechnica Award 2011. The specialist for technology transfer received the award from hands of Lower Saxony's Minister for Economy Jörg Bode. The...

SwitzerlandSwitzerland

01.10.2011

Liestal – Swiss Santhera AG has announced strict savings measures. Out of a total of 21 employees, almost every second is now slated to be sacked. The biotech firm is closing its department of preclinical development and scaling...

SwitzerlandSwitzerland

01.10.2011

Schlieren – Swiss biotechnology company Cytos AG has finally devised a plan to help its lead candidate into Phase II, but to achieve it, the cash-strapped company is having to slash its workforce by a whopping 85%. To ensure the...

SwitzerlandSwitzerland

01.10.2011

Geneva – Swiss biotech Addex Pharmaceuticals AG has regained all rights to its metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulator (PAM) programme from Merck&Co, (known as MSD outside the United States and...

SwitzerlandSwitzerland

01.10.2011

Hamburg – When the compound EVT302 failed proof-of-concept testing in the spring of 2009, investors began backing away from Evotec AG shares. Now the selective MAO-B inhibitor is back, and has powered a leap in the company’s...

SwitzerlandSwitzerland

15.09.2011

Zurich – The FDA has posted a manufacturing warning to Lonza following an inspection of the firm's microbial production site for Eisai’s cancer drug Ontak in Hopkinton. However, analysts at Vontobel said that the impact of the...

SwitzerlandSwitzerland

30.08.2011

Schlieren - Swiss biotechnology company Cytos has devised a plan to get its lead candidate into Phase II. To achieve this, the cash strapped company will slash its workforce, as previously announced, by 85%. To ensure the...

Displaying results 21 to 30 out of 276

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-switzerland/browse/2/article/santhera-publishes-pivotal-trial-results-of-idebenone-and-goes-for-eu-approval.html

Events

All Events

Stock list

All quotes

TOP

  • BIOFRONTERA2.44 EUR10.91%
  • WILEX2.19 EUR4.29%
  • PAION3.28 EUR1.86%

FLOP

  • SANTHERA83.00 CHF-4.54%
  • EVOLVA1.19 CHF-4.03%
  • BB BIOTECH149.65 EUR-2.95%

TOP

  • PAION3.28 EUR36.1%
  • CO.DON3.05 EUR24.0%
  • FORMYCON8.17 EUR15.9%

FLOP

  • CYTOS0.18 CHF-28.0%
  • EVOTEC3.05 EUR-18.0%
  • 4SC1.01 EUR-14.4%

TOP

  • SANTHERA83.00 CHF2044.7%
  • PAION3.28 EUR245.3%
  • CO.DON3.05 EUR214.4%

FLOP

  • CYTOS0.18 CHF-95.3%
  • 4SC1.01 EUR-46.0%
  • MOLOGEN6.64 EUR-44.2%

No liability assumed, Date: 01.10.2014


Current issue

All issues

Product of the week

Products